DISCUSSION IDEAS ABOUT MEDICINE AMBIGUITIES
https://doi.org/10.14412/1995-4484-2017-580-581
Abstract
The paper considers discussion ideas about the possible causes of medicine uncertainty that arose in the era of digital technologies and information flooding.
About the Authors
Yu. V. Muravyev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
L. A. Muravyev
Central Polyclinic Department, Khimki Central Clinical Hospital
Russian Federation
Russian Federation
2/21, Chkalov St., Khimki, Moscow Region 141400
References
1. Unnikrishnan MK. Eminence or Evidence? The Volatility, Uncertainty, Complexity, and Ambiguity in Healthcare. J Pharmacol Pharmacother. 2017;8(1):1-2. doi: 10.4103/jpp.JPP_12_17
2. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. PLoS Med. 2016;13:e1002127.
3. Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012;12: MR000033. doi: 10.1002/14651858.MR000033.pub2
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA. 2002;288(23):2998-3007. doi: 10.1001/jama.288.23.2998
5. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual careon primary cardiovascular prevention among older adults the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017 May 22. doi: 10.1001/jamainternmed.2017.1442 [Epub ahead of print].
6. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123. doi: 10.1136/bmj.f6123
7. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61. doi: 10.1016/S0140-6736(16)31357-5
8. Heath I, Evans S, Furberg C, et al. Report of the independent panel considering the retraction of two articles in the BMJ. BMJ. 2014;349:g5176. doi: 10.1136/bmj.g5176
9. Holleman F, Uijldert M, Donswijk LF, Gale EA. Productivity of authors in the field of diabetes: Bibliographic analysis of trial publications. BMJ. 2015;351:h2638. doi: 10.1136/bmj.h2638
10. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399-407. doi: 10.1002/art.22193
11. Aaltonen KJ, Ylikylä S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017;56(5):725-35. doi: 10.1093/rheumatology/kew467
Review
For citations:
Muravyev Yu.V., Muravyev L.A. DISCUSSION IDEAS ABOUT MEDICINE AMBIGUITIES. Rheumatology Science and Practice. 2017;55(5):580-581. (In Russ.) https://doi.org/10.14412/1995-4484-2017-580-581
Views:
601
Email this article 